Full text

Turn on search term navigation

© 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Background

Combined with systemic therapy, the surgical intervention for breast cancer liver metastases (BCLM) is increasingly accepted but lacks convincing evidence. The aim of this study was to evaluate the disease control efficacy of hepatic surgery in isolated BCLM patients.

Methods

Between 2012 and 2017, metastatic breast cancer patients with isolated liver metastasis and regular follow‐up were identified. Cohort design was conducted to compare the progression‐free survival (PFS) between the surgical and nonsurgical BCLM patients. Univariate analysis and multivariate Cox regression survival analyses were performed to identify significant prognostic factors.

Result

In all, 148 isolated BCLM patients were enrolled and 95 participants received hepatic surgery for metastatic lesions. With median follow‐up of 36.47 months, there was no significant difference between hepatic surgical group and nonsurgical group for PFS (median PFS: 11.17 months vs 10.10 m, P = .092). Based on the multivariate analysis, the disease‐free interval (DFI) was an independent prognostic factor for isolated BCLM patients. Among the surgical group, BCLM patients who had ideal response after first salvage systemic treatment experienced the best long‐term survival (median PFS: 14.20 months).

Conclusion

For isolated BCLM patients with ideal response in first‐line medical treatment, surgical intervention (hepatectomy, radiofrequency ablation) combining with systemic treatment could bring improved progression‐free survival compared to sole systemic treatment, indicating that hepatic surgery may be considered as a therapeutic choice for selected isolated BCLM patients in clinical practice.

Details

Title
The role of surgical intervention for isolated breast cancer liver metastasis: Results of case‐control study with comparison to medical treatment
Author
Wen, Jiahuai 1   VIAFID ORCID Logo  ; Ye, Feng 2 ; Xie, Fengfeng 3 ; Liu, Dan 3 ; Huang, LeZhen 3 ; Fang, Chen 3 ; Zhong, Shaowen 3 ; Ren, Liping 3 

 Department of Breast Oncology, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, China, The Standardized Training of Residents, Sun Yat‐Sen University Cancer Center, Guangzhou, China 
 Department of Breast Oncology, Sun Yat‐Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 
 Department of Breast Oncology, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, China 
Pages
4656-4666
Section
CLINICAL CANCER RESEARCH
Publication year
2020
Publication date
Jul 1, 2020
Publisher
John Wiley & Sons, Inc.
e-ISSN
20457634
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2419737297
Copyright
© 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.